drugset / Trial / NCT00913055
Open Label Study of Octreotide Implant in Patients With Acromegaly
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) response of a hydrated and non-hydrated 84 mg octreotide implant in patients with acromegaly in the first 6 weeks of treatment.
Timeline
- Start
- 2007-02
- Primary completion
- 2007-05
- Completion
- 2007-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Octreotide | Peptide | 84 mg | Subcutaneous |